BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord 2020;35:1727-30. [PMID: 33068466 DOI: 10.1002/mds.28240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects. Inflammopharmacology 2023. [PMID: 36961665 DOI: 10.1007/s10787-023-01192-2] [Reference Citation Analysis]
2 Menozzi E, Schapira AHV, Blandini F, Avenali M. Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach. Curr Neurol Neurosci Rep 2023. [PMID: 36881256 DOI: 10.1007/s11910-023-01259-1] [Reference Citation Analysis]
3 Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. Front Neurosci 2022;16:878239. [PMID: 35873830 DOI: 10.3389/fnins.2022.878239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Aasly JO. Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. Front Neurosci 2021;15:634666. [PMID: 33584195 DOI: 10.3389/fnins.2021.634666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]